

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sommadossi *et al.*

Serial No.: 09/864,078

Group Art Unit : 1623

Filed: May 23, 2001

Examiner: Howard Owens

Title: Methods and Compositions for Treating Hepatitis C Virus

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

August 26, 2003

Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,



Sherry M. Knowles, Esq.
Reg. No. 33,052

KING & SPALDING LLP
191 Peachtree Street
Atlanta, GA 30303
404-572-3451 (Telephone)
404-572-5145 (Facsimile)

#15
8-29-03
[Signature]
03 AUG 26 PM 3:29
RECEIVED

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/864,078
				Filing Date	23 May 2001
				First Named Inventor	Sommadossi, J-P. et al.
				Group Art Unit	1614
Sheet	1	of	1	Attorney Docket Number	06171.105022.

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number (if known)	Kind Code			
	A	2002/0147160	A1	Merck and Co. Inc.	October 10, 2002	
	B	2003/0060400	A1	Novirio (Idenix Pharmaceuticals Inc.)	March 27, 2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ² Number	Kind Code (if known)					
	C	WO	03/051899 A1	A1	Ribapharm Inc.	26-06- 2003		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.